title: Determination of dextromethorphan and its metabolite dextrorphan in human urine using high performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry: a study of selectivity of a tandem mass spectrometric assay.
abstract: Analytical method for the simultaneous determination of dextromethorphan (1) and dextrorphan (2) in urine, based on solid-phase extraction of drug from acidified hydrolyzed biological matrix, were developed. The analytes (1 and 2) and the internal standard (levallorphan, 3, IS) were detected by high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) in positive ionization mode using a heated nebulizer (HN) probe and monitoring their precursor-->product ion combinations of m/z 272-->215, 258-->201, and 284-->201 for 1, 2, and 3, respectively, in multiple reaction monitoring mode. The analytes and IS were chromatographed on a Keystone Prism reverse phase (50 mm x 2.0 mm) 5 microm column using a mobile phases consisting of a 35/65 or 27/73 mixtures of methanol/water containing 0.1% TFA adjusted to pH 3 with ammonium hydroxide pumped at 0.4 ml/min for 1 and 2, respectively. The limits of reliable quantification of 1 and 2 were 2 and 250 ng/ml, respectively, when 1 ml of urine was processed. The absence of matrix effect was demonstrated by analysis of neat standards and standards spiked into urine extracts originating from five different sources. The linear ranges of the assay were 2-200 and 250-20,000 ng/ml for 1 and 2, respectively. Assay selectivity was evaluated by monitoring the "cross-talk" effects from other metabolites into the MS/MS channels used for monitoring 1, 2, and 3. In addition, an interfering peak originating from an unknown metabolite of 1 into the quantification of dextromethorphan was detected, requiring an effective chromatographic separation of analytes from other metabolites of 1. The need for careful assessment of selectivity of the HPLC-MS/MS assay in the presence of metabolites, and the assessment of matrix effect, are emphasized.
authors.affiliation: Merck Research Laboratories, West Point, PA 19486, USA. marvin_constanzer@merck.com
authors.forename: M L
authors.initials: ML
authors.lastname: Constanzer
authors.forename: C M
authors.initials: CM
authors.lastname: Chavez-Eng
authors.forename: I
authors.initials: I
authors.lastname: Fu
authors.forename: E J
authors.initials: EJ
authors.lastname: Woolf
authors.forename: B K
authors.initials: BK
authors.lastname: Matuszewski
mesh_terms: D000996:Antitussive Agents / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003915:Dextromethorphan / Q000652:urine*; D003917:Dextrorphan / Q000652:urine*; D004355:Drug Stability; D005615:Freezing; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D015203:Reproducibility of Results
chemical_list: D000996:Antitussive Agents; D003917:Dextrorphan; D003915:Dextromethorphan